News

```htmlJinse Finance reported that on April 28, the US Dollar Index fell 0.03% on the 27th, closing at 98.231 in the foreign exchange market's late trading session.```

The team led by Matthew Hornbach pointed out that under Waller’s leadership, the Federal Reserve may adopt new inflation indicators, reduce forward guidance, and promote the shrinking of the balance sheet. These changes “may increase volatility between each rate-setting meeting.” Last week, Waller himself indicated in congressional testimony that the central bank’s “operational mechanisms for policy may undergo changes.” The team from Morgan Stanley emphasized that this constitutes a long-term shift and, therefore, did not propose new trading recommendations following Waller’s hearing. This aligns with current market conditions: US Treasury volatility this month is on track to be the narrowest since late 2020, highlighting a period of relative calm and prompting investors to search for new catalysts. “The hearing for Federal Reserve Chair nominee Kevin Waller shows that Federal Open Market Committee decisions will adopt new mechanisms, but it is not yet enough to trigger immediate position adjustments,” the team wrote in a report on Monday. “Waller made it clear that FOMC meetings may see more debate and divergence.”

According to a filing submitted by the Boston-based company to the U.S. Securities and Exchange Commission (SEC) on Monday, the company plans to issue 11.8 million shares, with each share priced between $16 and $18. Based on the upper limit of this range and the outstanding shares listed in the filing, the biotechnology company's market capitalization will reach $912 million. According to a presentation, the IPO is expected to be priced on April 30.